HOYA Corporation and Hitachi, Ltd. on 6 June 2020 announced a five-year contract regarding Endoscopic Ultrasound Systems [EUS] by which the parties will strengthen technical collaboration. Hitachi will continue supplying diagnostic ultrasound systems and ultrasound sensor-related parts used in EUS.
PENTAX Medical’s global chief marketing officer, David Woods, states “The C2 CryoBalloon Ablation System has the potential to improve the lives of millions of people around the world with pre-cancerous lesions of the esophagus,” Barrett’s esophagus and squamous dysplasia are both conditions in which the epithelial cells in the lining of the esophagus abnormally change to form “pre-cursor” lesions. If left untreated, these lesions can progress to esophageal cancer in some patients. The C2 CryoBalloon Ablation System provides the interventional endoscopist with a means to deliver a targeted dose of cryogen (extreme cold) to ablate these tissues immediately. Esophageal cancer is the 6th leading cause of cancer deaths in the world with a five-year survival rate of 18% and is the fastest growing form of cancer in the United States today.
FDA orders duodenoscope manufacturers to conduct postmarket surveillance